Champions Oncology Q3 revenue record $13.2M, up 22% YoY; adj. EBITDA $1.5M

CHAMPIONS ONCOLOGY, INC.

2022-Q3 EPS reported $0.06 revenue$36,232,000

Revenue of $13.2M for quarter ended Jan 31, 2022, a 22% increase from $10.8M in prior year.
Adjusted EBITDA was $1.5M; net income from operations of $830K (incl. $310K stock comp).
Gross margin for Q3 was 51.4% vs 57.2% a year ago; nine-month gross margin improved to 51.9% from 48.8%.
Cash position $8.7M with no debt; signed co-development partnerships with Fannin Innovation Studio and Gigamune.
Company reaffirms FY2022 revenue growth guidance of 15%-20%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.